

OPEN

A meta-analysis and systematic review of percutaneous catheter drainage in treating infected pancreatitis necrosis

Zhi-Hua Zhang, MD^a, Yi-Xuan Ding, MD^b, Yu-Duo Wu, MM^b, Chong-Chong Gao, MD^b, Fei Li, MD^{b,*}

Abstract

Background: In the current meta-analysis, we focus on the exploration of percutaneous catheter drainage (PCD) in terms of its overall safety as well as efficacy in the treatment of infected pancreatitis necrosis based on qualified studies.

Methods: The following electronic databases were searched to identify eligible studies through the use of index words updated to May 2018: PubMed, Cochrane, and Embase. Relative risk (RR) or mean difference (MD) along with 95% confidence interval (95% CI) were utilized for the main outcomes.

Results: A total of 622 patients in the PCD group and 650 patients in the control group from 13 studies were included in the present meta-analysis. The aggregated results indicated that the incidence of bleeding was decreased significantly (RR: 0.42, 95% CI: 0.25–0.70) in the PCD group as compared with the control group. In addition, PCD decreased the mortality (RR: 0.76, 95% CI: 0.41–1.42), hospital duration (SMD: -0.22, 95% CI: -0.77 to -0.33), duration in intensive care unit (ICU) (SMD: -0.13, 95% CI: -0.30 to -0.04), pancreatic fistula (RR: 0.73, 95% CI: 0.46–1.17), and organ failure (RR: 0.91, 95% CI: 0.45–1.82) in comparison with the control group, but without statistical significance.

Conclusion: Our findings provide evidence for the treatment effect of PCD in the decrease of bleeding, mortality, duration in hospital and ICU, pancreatic fistula, organ failure as compared with the surgical treatment. In conclusion, further studies based on high-quality RCTs with larger sample size and long-term follow-ups are warranted for the confirmation of PCD efficacy in treating infected pancreatitis necrosis.

Abbreviations: CI = confidence interval, MD = mean difference, OR = odds ratio, PCD = percutaneous catheter drainage, RR = relative risk, VARD = video-assisted restroperitoneal debridement.

Keywords: inguinal hernias, laparoscopic, lichtenstein, meta-analysis

1. Introduction

Acute pancreatitis is commonly diagnosed gastrointestinal disorder disease, which contributes to about 270,000 inpatients annually and costs more than 2.5 billion dollars for outpatients in the United States.^[1] Necrotizing pancreatitis has been reported to account for 10% to 15% patients harboring acute pancreatitis, with or without infection.^[2] It is acknowledged to be manageable for sterile pancreatic necrosis, while infected pancreatitis necrosis is associated with varying mortality rate of 20% to 30% and

Received: 6 August 2018 / Accepted: 4 October 2018 http://dx.doi.org/10.1097/MD.000000000012999 leading to 40% if accompanied with organ failure.^[3,4] The traditional treatment for infected pancreatitis necrosis is open necrosectomy that contribute to the removal of necrotic tissue as well as the drainage of infected compartments. In addition, open necrosectomy may lead to various complications with as high as 11% to 39% in the mortality rate.^[5-7] In the past decades,</sup> minimally invasive technique has been analyzed among several published studies. The minimally invasive techniques currently include the following approaches: endoscopic necrosectomy video-assisted restroperitoneal debridement (VARD), minimally invasive necrosectomy, and percutaneous catheter drainage (PCD).[8-10] PCD has been regarded as the least invasive procedure in treating infected pancreatitis necrosis, with reduced infected fluid under pressure and the infection level, stable symptoms, and less complications.^[11] Hence, we conducted the current meta-analysis based on qualified studies to explore the overall effectiveness of PCD in terms of treating infected pancreatitis necrosis.

2. Methods

2.1. Search strategy and study collection

A wide electronic search of the following databases, such as the PubMed, Embase, and Cochrane, was performed to identify eligible studies concerning PCD vs surgical treatment for infected pancreatitis necrosis updated to May 2018. We also searched other associated publications as well as reference lists. Studies

Editor: Babić Žarko.

This study was supported by funds from Beijing Municipal Administration of Hospitals Clinical Medicine Development (grant no: XMLX201404).

The authors have no conflicts of interest to disclose.

^a Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, ^b Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.

^{*} Correspondence: Fei Li, Department of General Surgery, Xuanwu Hospital, Capital Medical University, No 45 Changchun Street, Xicheng District, Beijing, China (e-mail: feili36@ccmu.edu.cn).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:47(e12999)

were screened separately by 2 investigators; any difference was resolved through the aid of 3rd party to reach a consensus.

2.2. Study selection and criteria

Studies were required to be included based on the following inclusion criteria: clinical study that analyzed the efficacy of PCD in the treatment of infected pancreatitis necrosis; the included patients were diagnosed with infected pancreatitis necrosis; the 2 groups were treated with PCD and surgical treatment respectively; the outcomes included one of the following parameters: mortality, duration in hospital and ICU, bleeding, pancreatic fistula, organ failure.

Studies should be excluded if the following exclusion criteria were met: repeat publications, or shared content and results; economic analysis, expert comment, theoretical research, metaanalysis, systematic review, case report, conference report; and irrelevant outcomes.

Two authors screened and checked separately to identify eligible studies according to predefined criteria; any disagreements were settled through the discussion with a 3rd author.

2.3. Statistical extraction and evaluation

The analyses data from eligible studies were collected by 2 reviewers, including basic information and main outcomes. Basic information included the following parameters: the name of author, the year of publication, the study design, the treatment method, the sample size, the gender, the age. Furthermore, clinical outcomes included duration in hospital and ICU, mortality, bleeding, pancreatic fistula, as well as organ failure. The above-mentioned evaluation process was separately conducted by 2 investigators; any arising differences were settled by general consensus.

2.4. Statistics analysis

The meta-analysis was conducted through the use of the STATA 10.0 (College station, TX). Heterogeneity of the trial results was assessed with the I^2 tests value and *P*-value to select ideal analysis model (random-effect model or fixed-effect model): $I^2 > 50\%$ and Chi-squared test $P \leq .05$ reflected a high heterogeneity and random-effects model was utilized; $I^2 \leq 50\%$ and Chi-squared test P > .05 reflected an acceptable heterogeneity data with the assessment of fixed-effects model. For the continuous variables, they were analyzed by mean difference (MD) and expressed as the mean \pm standard deviation. We calculated and presented the categorical data as percentages and analyzed the data through the use of odds ratio (OR) or relative risk (RR). OR and its 95% CI were used to analyze all the risk factors. Mortality, bleeding, pancreatic fistula, and organ failure were analyzed by RR and 95% CI. Duration in hospital and ICU were also under the evaluation with the use of MD and 95% CI.

3. Results

3.1. Study characteristics

Through the search of indexes, a total of 1219 publications were included. After title and abstract screening, 1135 publications were then excluded, thus 84 publications were left for further assessment. During full-text screening, 71 publications were excluded due to: case report (5), diagnosis study (8), has nonclinical outcomes (30), theoretical research, or review (28). Therefore, a final total of 13 studies^[8,12–23] that included 15 compared groups were presented in the meta-analysis, of which 622 patients were evaluated in the PCD group and 650 in the control group (Fig. 1).

Table 1 revealed the major characteristics of studies. The study design included retrospective or prospective cohort study, clinical study, and randomized controlled trial. The therapy of PCD group contained PCD, minimally invasive PCD, and image-guide PCD. The therapy of control group contained surgical necrosectomy, video-assisted retroperitoneal debridement, conservative treatment, and open laparotomy. The current study contained patients with mean age of above 40, and other information such as sample, gender, and APACHE II score.

3.2. Mortality

Twelve trials with a total of 605 and 633 patients that were evaluated respectively in PCD and control group provided the data about the mortality. On basis of the I^2 tests value ($I^2 = 58.0\%$) and Chi-squared test *P*-value (*P*=.003), random effect model was used to analyze the mortality. The pooled results revealed that there was no remarkable difference in mortality between the 2 study groups (RR: 0.76, 95% CI: 0.41–1.42, Fig. 2).

3.3. Length of hospital stay

Six trials with a total of 372 and 266 patients that were evaluated respectively in PCD group and control group provided the data about the length of hospital stay. I^2 tests value (I^2 = 88.2%) and Chi-squared test *P*-value (*P* = .000) were calculated with random effect model to analyze the length of hospital stay. The aggregated results revealed no significant difference of the length of hospital stay when comparing the 2 study groups (SMD: -0.22, 95% CI: -0.77 to -0.33, Fig. 3).

3.4. Length of ICU stay

Six trials with a total of 372 and 266 patients that were evaluated respectively in PCD group and control group provided the data about the length of ICU stay. According to the I^2 tests value ($I^2 = 0.8\%$) and Chi-squared test *P*-value (P = .418), fixed effect model was applied to analyze the length of ICU stay. The aggregated results revealed no remarkable difference when comparing the 2 study groups in the length of ICU stay (SMD: -0.13, 95% CI: -0.30 to -0.04, Fig. 4).

3.5. Pancreatic fistula

Four trials with a total of 286 and 148 patients that were evaluated respectively in PCD group and control group provided the data about the pancreatic fistula. I^2 tests value ($I^2 = 0.0\%$) and Chi-squared test *P*-value (*P*=.875) were calculated with fixed effect model to analyze the pancreatic fistula. According to pooled results, no significant difference was observed in the pancreatic fistula when comparing the 2 study groups (RR: 0.73, 95% CI: 0.46–1.17, Fig. 5).

3.6. Bleeding

Seven trials with a total of 395 and 441 patients that were evaluated respectively in PCD group and control group provided the data



about the bleeding. I^2 tests value ($I^2 = 16.4\%$) and Chi-squared test *P*-value (P = .301) with the use of fixed effect model to analyze the bleeding. Based on the pooled results, the bleeding incidence was significantly decreased in the PCD group in comparison of the control group (RR: 0.42, 95% CI: 0.25–0.70, Fig. 6).

3.7. Organ failure

Eight trials with a total of 251 and 477 patients that were evaluated respectively in PCD group and control group provided

the data about the organ failure. I^2 tests value ($I^2 = 87.4\%$) and Chi-squared test *P*-value (*P* = .000) with the use of random effect model to analyze the organ failure. Based on the pooled results, there was no significant difference between the 2 groups in terms of the organ failure (RR: 0.91, 95% CI: 0.45–1.82, Fig. 7).

3.8. Quality assessment and potential bias

On the basis of the predefined criteria, a total of 13 publications were analyzed in the current systematic review. We applied the

 Table 1

 The major characteristics of the qualified studies in more detail.

				Sample	e size	
Study	Publication year	Study design	Study period	MI-TLIF	0-TLIF	Pathology
Tian	2014	Prospective observational study	2010-2011	30	31	Symptomatic degenerative disease of the lumbosacral spine (L2-S1)
Sulaiman	2014	Prospective observational study	2009-2012	57	11	Degenerative spondylolisthesis
Singh	2014	Retrospective observational study	2008–2010	33	33	Lumbar degenerative disc disease (DDD), degenerative spondylolisthesis, or spinal stenosis
Parker	2014	Prospective observational study	Not report	50	50	Lumbar spondylolisthesis
Gu	2014	Prospective observational study	2010-2011	44	38	Two-level lumbar degenerative disease
Terman	2014	Retrospective observational study	2007-2011	53	21	Lumbar DDD, herniated disc, listhesis, stenosis
Zhang	2017	Retrospective observational study	2014-2017	48	59	Single-level lumbar instability or degenerative disk disease
Kulkarmi	2016	Prospective observational study	2011-2013	36	25	Back and leg pain secondary to degenerative disease
Serban	2017	Prospective randomized study	2011–2015	40	40	Symptomatic with low back pain plus radicular pain and/or neurogenic claudication
Wu	2018	Retrospective observational study	2010-2015	79	88	grade I or II single segmental spondylolisthesis

	Expe	rimenta	al	C	Control			Std. Mean Difference		erence			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI			
Gu 2014	145.5	21.5	79	151.4	19.9	88	15.5%	-0.28 [-0.59, 0.02]			-		
Kulkarmi 2016	204	0.54	36	177.6	0.57	25	2.0%	47.18 [38.51, 55.85]			1		
Serban 2017	321.92	85.57	40	296.22	101.01	40	15.3%	0.27 [-0.17, 0.71]			- + -		
Singh 2014	115.8	28.2	33	186	31	33	15.1%	-2.34 [-2.98, -1.71]					
Sulaiman 2014	161	7.6	57	375	14	11	6.1%	-23.85 [-28.03, -19.67]			-		
Tian 2014	159.2	20.12	30	113.06	23.19	31	15.1%	2.10 [1.46, 2.73]			- F		
Wu 2018	145.5	21.5	79	151.4	19.9	88	15.5%	-0.28 [-0.59, 0.02]					
Zhang 2017	146	15	48	136	25	59	15.4%	0.47 [0.08, 0.86]			- t		
Total (95% CI)			402			375	100.0%	-0.51 [-1.84, 0.81]					
Heterogeneity: Tau ² =	2.93: Ch	$i^2 = 346$	5.29. d	f = 7 (P <	0.0000	1): $ ^2 =$	98%				_		
Test for overall effect									-100	-50	MIS Ope	50	100

Figure 2. Forest plot showing the mortality of percutaneous catheter drainage vs surgical treatment.

	Exp	erimenta	1	C	Control			Std. Mean Difference			Std. Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, F	Random, 9	5% CI			
Gu 2014	248.4	94.3	44	576.8	176.2	38	13.3%	-2.35 [-2.92, -1.78]							
Serban 2017	351.25	198.87	40	417.5	211.69	40	13.5%	-0.32 [-0.76, 0.12]			-				
Singh 2014	124.4	92	33	380.3	191.2	33	13.3%	-1.69 [-2.25, -1.12]			-				
Sulaiman 2014	95	20	57	786	107	11	6.9%	-15.00 [-17.68, -12.32]			-				
Terman 2014	100	20	53	450	140	21	12.4%	-4.57 [-5.48, -3.66]							
Tian 2014	142.17	72.01	30	231.29	109.84	31	13.4%	-0.94 [-1.48, -0.41]			-				
Wu 2018	163.7	49.6	79	243.3	70.2	88	13.7%	-1.29 [-1.63, -0.96]			-				
Zhang 2017	186	95	48	296	97	59	13.6%	-1.14 [-1.55, -0.72]			1				
Total (95% CI)			384			321	100.0%	-2.64 [-3.62, -1.65]							
Heterogeneity: Tau ² =	1.82: Ch	i ² = 185.	42. df	= 7 (P <	0.00001)	$ ^2 = 9$	6%			1.	-	-			
Test for overall effect							7775×.		-100	-\$0	MIS Ope	50	100		

Figure 3. Forest plot showing the length of hospital stay of percutaneous catheter drainage versus surgical treatment.

	Expe	rimen	tal	(Control			Std. Mean Difference			Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV,	Randor	n, 95%	CI	
Kulkarmi 2016	4.11	1.8	36	5.84	2.249	25	16.8%	-0.86 [-1.39, -0.32]				-		
Singh 2014	2.3	1.2	33	2.9	1.1	33	17.0%	-0.52 [-1.01, -0.02]						
Sulaiman 2014	3.6	1	57	3.2	0.2	11	16.3%	0.43 [-0.22, 1.08]						
Terman 2014	2	0.2	53	3	0.4	21	15.6%	-3.65 [-4.44, -2.87]			-			
Tian 2014	4.53	30	558	0.79	31	0		Not estimable			I			
Wu 2018	5.8	1.4	36	5.84	2.249	25	16.9%	-0.02 [-0.53, 0.49]						
Zhang 2017	7.9	2.8	48	10.1	3.2	59	17.4%	-0.72 [-1.11, -0.33]			- 1			
Total (95% CI)			821			174	100.0%	-0.86 [-1.70, -0.02]						
Heterogeneity: Tau ² =	= 1.01; C	:hi ² =	73.12,	df = 5	(P < 0.0	00001)	l ² = 93%		-100	-50			50	100
Test for overall effect	Z = 2.0	2 (P =	0.04)						-100	-30	MIS	Open	50	100

Figure 4. Forest plot showing the length of intensive care unit stay of percutaneous catheter drainage versus surgical treatment.

Medicine

	Experim	ental	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Sulaiman 2014	4	57	2	11	11.0%	0.39 [0.08, 1.85]	
Terman 2014	9	53	11	21	51.6%	0.32 [0.16, 0.67]	
Tian 2014	2	30	2	31	6.4%	1.03 [0.16, 6.87]	
Wu 2018	7	79	10	88	31.0%	0.78 [0.31, 1.95]	
Total (95% CI)		219		151	100.0%	0.52 [0.31, 0.86]	•
Total events	22		25				200
Heterogeneity: Chi ² =	3.03, df =	= 3 (P =	0.39); 1	= 1%			
Test for overall effect	: Z = 2.53	(P = 0.	01)				0.01 0.1 1 10 100 MIS Open

Figure 5. Forest plot showing the pancreatic fistula of percutaneous catheter drainage versus surgical treatment.

	Expe	Experimental Control						Std. Mean Difference	Std. Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV,	Random, 9	5% CI		
Parker 2014	4.8	3.4	50	4.9	3.1	50	26.2%	-0.03 [-0.42, 0.36]				Station Company		
Sulaiman 2014	3.2	0.89	57	5.1	0.99	11	21.8%	-2.07 [-2.81, -1.33]			-			
Tian 2014	1.3	0.34	30	1.16	0.44	31	24.9%	0.35 [-0.16, 0.86]						
Wu 2018	1.63	1.2	79	1.84	0.99	88	27.1%	-0.19 [-0.50, 0.11]			- t			
Total (95% CI)			216			180	100.0%	-0.42 [-1.13, 0.28]						
Heterogeneity: Tau ² = Test for overall effect:					(P < 0	.00001); $l^2 = 900$	%	-100	-50	MIS Op	50	100	

Mazumdar and Begg rank test, Egger test, as well as funnel plot to further check the potential bias and quality of studies. The funnel plot for log RR in mortality was remarkably symmetrical, indicating there was no significant publication bias (Fig. 8). Additionally, evidential symmetry was observed through the assessment of Mazumdar and Begg rank test (Z=1.64, P=.101). Additionally, no remarkable publication bias was indicated from the results of the Egger test (P=.143).

4. Discussion

Several meta-analyses as well as systematic reviews have been published, regarding the effect of PCD in terms of treating infected pancreatitis necrosis. Reports supported by Ke et al^[2] found that about 55.3% patients suffered from organ failure before PCD. About as high as 56.2% patients gained beneficial treatment effects with PCD alone and 38.5% should seek extra surgical intervention after PCD. Fistula commonly occurred as one of the complications affecting 25.1% patients with a mortality rate of 18% in general (104 out of 577). It is considered as an efficient as well as alternative method in treating patients harboring infected pancreatitis necrosis with intervention of PCD alone. Aggregated reports have revealed that the negative parameters include multiple organ failures that occur before PCD treatment. No strong evidence has been showed the superior effect of large catheters in draining necrotic tissue. Nevertheless, difficulty exists in terms of determining single prognostic factor for the extent of multi-morbid individuals. Cirocchi et al^[24] found that, when comparing open necrosectomy (ON) surgery with minimally invasive necrosectomy (MIN) for the therapy of infected necrosis of acute pancreatitis, superior treatment effect of MIN was observed with regards to the following outcomes: new-onset diabetes (OR, 0.32; 95% CI: 0.12-0.88), incisional hernias (OR, 0.23; 95% CI: 0.06-0.90), incidence of multiple organ failure (OR, 0.16; 95% CI: 0.06-0.39), as well as for the use of pancreatic enzymes (OR, 0.005; 95% CI: 0.04–0.57). In addition, there were no remarkable difference concerning the intraabdominal bleeding (OR, 0.79; 95% CI: 0.41-1.50), multiple systemic complications (OR, 0.34; 95% CI: 0.01-8.60), pancreatic fistula (OR, 0.66; 95% CI: 0.30–1.46), mortality rate (OR, 0.43; 95% CI: 0.18–1.05), surgical reintervention for further necrosectomy (OR, 0.16; 95% CI: 0.00-3.07), surgical reintervention for postoperative complications (OR, 0.50; 95% CI: 0.23-1.08), and







enterocutaneous perforation or fistula of visceral organs (OR, 0.52; 95% CI: 0.27–1.00).

To our knowledge, however, several limitations exited that should not be ignored in the present meta-analysis, including: retrospective researches in most studies; different selection criteria for patients in various trials and studies; various surgical technique in different trials; we used pooled data for analyses with unavailable individual data, which limited for more comprehensive analyses.

Given the overall results of our analysis, the present study offers moderate evidence to prove the beneficial effect of PCD in decreasing the incidence of bleeding, mortality, duration in hospital and ICU, pancreatic fistula, and organ failure. While no significant differences were observed between PCD and surgical treatment. Therefore, additional high-quality RCTs with larger sample size and longer follow-ups are in great need for the confirmation of PCD efficacy in treating infected pancreatitis necrosis.

Author contributions

Conceptualization: Zhi-Hua Zhang, Fei Li.

Data curation: Yi-Xuan Ding, Yu-Duo Wu, Chong-Chong Gao. Formal analysis: Yi-Xuan Ding, Yu-Duo Wu, Chong-Chong Gao.

Investigation: Yu-Duo Wu, Chong-Chong Gao.

Writing - original draft: Zhi-Hua Zhang, Fei Li.

Writing – review & editing: Fei Li.

References

- Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179–87.
- [2] Ke L, Li J, Hu P, et al. Percutaneous catheter drainage in infected pancreatitis necrosis: a systematic review. Indian J Surg 2016;78: 221–8.
- [3] van Santvoort HC, Bakker OJ, Bollen TL, et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. Gastroenterology 2011;141:1254–63.
- [4] Petrov MS, Shanbhag S, Chakraborty M, et al. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology 2010;139:813–20.
- [5] Zorger N, Hamer OW, Feuerbach S, et al. Percutaneous treatment of a patient with infected necrotizing pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2005;2:54–7.
- [6] Gmeinwieser J, Holstege A, Zirngibl H, et al. Successful percutaneous treatment of infected necrosis of the body of the pancreas associated with segmental disruption of the main pancreatic duct. Gastrointest Endosc 2000;52:413–5.
- [7] Cheung MT, Ho CN, Siu KW, et al. Percutaneous drainage and necrosectomy in the management of pancreatic necrosis. ANZ J Surg 2005;75:204–7.

- [8] van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010;362:1491–502.
- [9] van Baal MC, van Santvoort HC, Bollen TL, et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. Br J Surg 2011;98:18–27.
- [10] Hollemans RA, van Brunschot S, Bakker OJ, et al. Minimally invasive intervention for infected necrosis in acute pancreatitis. Expert Rev Med Devices 2014;11:637–48.
- [11] Tong ZH, Li WQ, Yu WK, et al. The clinical effectiveness of percutaneous drainage and laparotomy for patients with infective pancreatic necrosis [in Chinese]. Zhonghua wai ke za zhi 2010;48: 1387–91.
- [12] Bruennler T, Langgartner J, Lang S, et al. Outcome of patients with acute, necrotizing pancreatitis requiring drainage-does drainage size matter? World J Gastroenterol 2008;14:725–30.
- [13] Zerem E, Imamovic G, Susic A, et al. Step-up approach to infected necrotising pancreatitis: a 20-year experience of percutaneous drainage in a single centre. Dig Liver Dis 2011;43:478–83.
- [14] Tong Z, Li W, Yu W, et al. Percutaneous catheter drainage for infective pancreatic necrosis: is it always the first choice for all patients? Pancreas 2012;41:302–5.
- [15] Horvath K, Freeny P, Escallon J, et al. Safety and efficacy of videoassisted retroperitoneal debridement for infected pancreatic collections: a multicenter, prospective, single-arm phase 2 study. Arch Surg 2010;145:817–25.
- [16] Rocha FG, Benoit E, Zinner MJ, et al. Impact of radiologic intervention on mortality in necrotizing pancreatitis: the role of organ failure. Arch Surg 2009;144:261–5.
- [17] He WH, Zhu Y, Zhu Y, et al. The outcomes of initial endoscopic transluminal drainage are superior to percutaneous drainage for patients with infected pancreatic necrosis: a prospective cohort study. Surg Endosc 2017;31:3004–13.
- [18] Li A, Cao F, Li J, et al. Step-up mini-invasive surgery for infected pancreatic necrosis: results from prospective cohort study. Pancreatology 2016;16:508–14.
- [19] Guo Q, Li A, Hu W. Predictive factors for successful ultrasound-guided percutaneous drainage in necrotizing pancreatitis. Surg Endosc 2016;30:2929–34.
- [20] Sugimoto M, Sonntag DP, Flint GS, et al. Better outcomes if percutaneous drainage is used early and proactively in the course of necrotizing pancreatitis. J Vasc Interv Radiol 2016;27:418–25.
- [21] Peng T, Dong LM, Zhao X, et al. Minimally invasive percutaneous catheter drainage versus open laparotomy with temporary closure for treatment of abdominal compartment syndrome in patients with earlystage severe acute pancreatitis. J Huazhong Univ Sci Technol Med Sci 2016;36:99–105.
- [22] Sugimoto M, Sonntag DP, Flint GS, et al. A percutaneous drainage protocol for severe and moderately severe acute pancreatitis. Surg Endosc 2015;29:3282–91.
- [23] Gou S, Yang C, Yin T, et al. Percutaneous catheter drainage of pancreatitis-associated ascitic fluid in early-stage severe acute pancreatitis. Pancreas 2015;44:1161–2.
- [24] Cirocchi R, Trastulli S, Desiderio J, et al. Minimally invasive necrosectomy versus conventional surgery in the treatment of infected pancreatic necrosis: a systematic review and a meta-analysis of comparative studies. Surg Laparosc Endosc Percutan Tech 2013;23: 8–20.